SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-012543
Filing Date
2023-02-17
Accepted
2023-02-16 20:21:34
Documents
13
Period of Report
2023-02-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea173875-8k_tffpharma.htm   iXBRL 8-K 25854
2 INVESTOR PRESENTATION SCRIPT ea173875ex99-1_tffpharma.htm EX-99.1 33418
  Complete submission text file 0001213900-23-012543.txt   245952

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tffp-20230216.xsd EX-101.SCH 3230
4 XBRL LABEL FILE tffp-20230216_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tffp-20230216_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea173875-8k_tffpharma_htm.xml XML 3702
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 23640038
SIC: 2834 Pharmaceutical Preparations